Ohio is currently home to 3229 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
NCT05543616
Recruiting
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in. * Substudy A design: Phase 1 includes participa... Read More
Gender:
ALL
Ages:
Between 6 months and 11 years
Trial Updated:
05/13/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Register for Updates
The Parkinson's Genetic Research Study
NCT01558479
Recruiting
The Parkinson's Genetic Research Study (PaGeR), headed by Dr. Cyrus Zabetian, is searching for genes that increase the risk of developing Parkinson's disease (PD) and related disorders. The study is a joint effort by neurologists and researchers across the United States and is sponsored by the National Institutes of Health. The coordinating center for PaGeR is located at the University of Washington and the VA Puget Sound Health Care System in Seattle.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/11/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Parkinson's Disease
Register for Updates
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
NCT04655118
Recruiting
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment, or be diagnosed with Indolent Systemic Mastocytosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Gabrail Cancer Center, Canton, Ohio
Conditions: Myelofibrosis, Indolent Systemic Mastocytosis
Register for Updates
PARTNER 3 Trial - Aortic Valve-in-Valve
NCT03003299
Recruiting
This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
Gender:
ALL
Ages:
All
Trial Updated:
05/08/2024
Locations: The Christ Hospital, Cincinnati, Ohio
Conditions: Aortic Stenosis, Aortic Stenosis, Severe
Register for Updates
Technology-assisted Language Intervention (TALI)
NCT04857255
Recruiting
This study is testing the effectiveness of augmentative and alternative communication technology among deaf or hard of hearing children for improving language development. Children will be randomized to receive either the technology intervention or treatment as usual
Gender:
ALL
Ages:
Between 3 years and 10 years
Trial Updated:
05/07/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hearing Loss, Bilateral, Language Development
Register for Updates
Evaluating the Technology and Assessing the Biological Effects of Commercially Available PhotoBioModulation Devices
NCT06403644
Recruiting
Photobiomodulation therapy (PBMT) involves applying non-ionizing forms of light from sources including lasers, LEDs, and broadband light, in the visible and near infrared spectrum, to the body to enhance performance, stimulate healing, modulate recovery, and improve health. The investigators will conduct a single-blinded randomized-control trial with sham control to investigate the effectiveness of providing PBMT in a military population, translating this cutting-edge research to application in... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
05/03/2024
Locations: Wright Patterson Air Force Base, Beavercreek, Ohio
Conditions: Physiological Wellness
Register for Updates
Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
NCT06403605
Recruiting
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on 2 commercially available SOC treatments for Diabetic Foot Wounds.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2024
Locations: Lower Extremity Institute for Research and Therapy, Youngstown, Ohio
Conditions: Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot
Register for Updates
Effects of Remote Cardiac Ischemic Preconditioning
NCT06390358
Recruiting
A heart attack occurs when blood flow is disrupted to the heart and is related to both the blockage and flow restoration (reperfusion injury). An occlusion during a heart attack can be cleared (mostly via stents), but there are no methods to decrease reperfusion injury even though animal studies have found that "preconditioning" has powerful protective effects. Through the observation of Jewish men wearing tefillin the investigators have discovered a method of bringing preconditioning to patient... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Cardiac Function and Preconditioning
Register for Updates
Genetic and Cognitive Predictors of Aphasia Treatment Response
NCT05179538
Recruiting
Aphasia, or language impairment after a stroke, affects approximately 2 million people in the United States, with an estimated 180,000 new cases each year. The medical community cannot predict how well someone with aphasia will respond to treatment, as some people with aphasia are poor responders to intervention even when participating in empirically supported treatments. There is a strong likelihood that genetics play a role in language recovery after stroke, but very little research has been d... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/02/2024
Locations: The Ohio State University, Columbus, Ohio
Conditions: Aphasia
Register for Updates
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06399393
Recruiting
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Multiple Myeloma
Register for Updates
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
NCT05845593
Recruiting
This is an open label study to determine the association of the data obtained with LuGENE®, a transcriptomic-based LDT, with standard evaluation of patients diagnosed with SLE, including clinical involvement, SLEDAI score, Physician Global Assessment (PGA) and standard laboratory measures, including ANA, anti-DNA, anti-RNP and complement components C3 and C4, as well as Patient Reported Outcomes capturing pain, fatigue and Health-Related Quality of Life. The test will be administered on one occa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Lupus Erythematosus, Systemic
Register for Updates
Novel Amblyopia Treatment With Virtual Reality Games
NCT06049459
Recruiting
The goal of this study is to compare the change in amblyopic eye acuity between treatment periods in children with amblyopia, aged 5-17 years. The main question it aims to answer is: Is a 16-week course of amblyopia treatment using Vivid Vision Therapeutic (Dichoptic) Virtual Reality Games for approx. 25 min/day, 6 days/week more effective for improvement in amblyopic-eye VA, binocularity (stereoacuity, suppression, alignment), contrast sensitivity, attention, oculomotor function, visual-motor... Read More
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
04/30/2024
Locations: The Ohio State University College of Optometry, Columbus, Ohio
Conditions: Amblyopia
Register for Updates